Alfresa Pharma, Tanabe Seiyaku to Collaborate in Development and Sales of Narcolepsy Drug Modafinil.Tokyo, Japan, Apr 5, 2006 - (JCN) - Alfresa Pharma, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Alfresa Holdings, has signed an agreement with Tanabe Seiyaku on modafinil, an agent for treating narcolepsy. Upon receiving approval, the two companies will co-promote the agent under the trade name of Modiodal in Japan. Further, they will proceed with research on the agent with the aim of expanding indications including obstructive sleep apnea Obstructive sleep apnea (OSA) A potentially life-threatening condition characterized by episodes of breathing cessation during sleep alternating with snoring or disordered breathing. syndrome and pediatric ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or (attention-deficit hyperactivity disorder Attention-deficit hyperactivity disorder (ADHD) A condition in which a person (usually a child) has an unusually high activity level and a short attention span. People with the disorder may act impulsively and may have learning and behavioral problems. ). Modafinil is an arousal-enhancing agent for which Alfresa Pharma has obtained rights to develop, manufacture and develop in Japan from US company Cephalon. Currently, the agent is available in over 30 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion